Eisai Co

Eisai Co EBIT per Share

The EBIT per Share of Eisai Co (4523.T) as of Oct 28, 2026 is 142.64 JPY. In the previous year, EBIT per Share was 174.54 JPY — a change of -18.28% (lower).

EBIT per Share

142.64JPY

YoY

-18.28%

Last updated:

EBIT per Share of Eisai Co is 2026 142.64 JPY. EBIT per Share of Eisai Co was 2025 174.54 JPY. It decreases by -18.28% lower compared to the previous year.

The Eisai Co EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2024
165.72 JPY
Jan 1, 2025
174.54 JPY
Jan 1, 2026
142.64 JPY
Jan 1, 2027 (e)
258.07 JPY
Jan 1, 2028 (e)
295.54 JPY
Jan 1, 2029 (e)
301.00 JPY
Jan 1, 2030 (e)
353.20 JPY
Jan 1, 2031 (e)
398.67 JPY
The Eisai Co EBIT per Share history
YEAREBIT per ShareYoY
est398.67JPY+12.87%
est353.20JPY+17.34%
est301.00JPY+1.85%
est295.54JPY+14.52%
est258.07JPY+80.93%
142.64JPY-18.28%
174.54JPY+5.32%
165.72JPY+21.19%
136.75JPY-34.22%
207.89JPY+5.42%
197.20JPY-59.23%
483.68JPY+38.76%
348.57JPY+32.19%
263.68JPY+47.54%
178.72JPY+19.67%
149.34JPY+54.19%
96.86JPY-56.85%
224.46JPY-8.64%
245.69JPY-26.84%
335.81JPY-15.40%
396.93JPY+31.75%
301.28JPY-5.88%
320.12JPY+417.26%
61.89JPY-83.43%
373.42JPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Eisai Co Stock analysis

What does Eisai Co do? Eisai Co Ltd is a Japanese pharmaceutical company based in Tokyo that specializes in research, development, production, and marketing of pharmaceuticals. The company was founded in 1936 by Shinjiro Torii, who had previously worked as a chemist at another pharmaceutical company. Eisai began its journey in the production of medicines, especially herbal medicine known in Japan, which are sold as OTC products. Eisai grew rapidly and started producing antibiotics in 1947. Over the following decades, the company expanded into the global market and is now present in over 20 countries. Eisai is dedicated to creating innovations as its main business model in order to help patients worldwide through its range of products. With this mission, the company has developed and introduced hundreds of drugs to the market, improving the quality of life for millions of people around the world. The company is divided into several business segments, including neurology, oncology, coagulation disorders, and gastrointestinal diseases. Eisai specializes in developing innovative drugs targeting a wide range of human diseases. Eisai is particularly known today for its leading position in Alzheimer's and dementia research. An important milestone in the company's history was the discovery of Aricept, a medication used to treat Alzheimer's disease. Eisai was the first Japanese company to develop a drug approved by the US FDA. Other products from Eisai include Lenvima, a medication for the treatment of thyroid cancer, and Lusedra, a sedative for anesthesia induction and maintenance for patients undergoing surgery. Eisai invests significantly in research and development to maintain its position as an innovation leader in the pharmaceutical manufacturing industry. The company collaborates with leading academic institutions and research organizations to make groundbreaking discoveries in various medical fields. Eisai also places importance on social responsibility and is involved in numerous social projects such as supporting Japan against cancer and providing consultation for elderly home care. The company aims to contribute to making the healthcare system more sustainable and equitable. Overall, Eisai is a leading pharmaceutical company with a strong focus on creating innovations to improve human health. It has a wide range of products and continuously works on developing new drugs and therapies to help patients worldwide. Eisai Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Eisai Co stock

EBIT per Share of Eisai Co is 142.64 JPY in 2026.

EBIT per Share of Eisai Co changed from 174.54 JPY to 142.64 JPY, representing a -18.28% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Eisai Co since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Eisai Co

All Key Metrics — Eisai Co